NIH Research Evaluation and Commercialization Hubs (REACH) Awards (U01 Clinical Trial Not Allowed)

archived

The National Institutes of Health (NIH) intends to publish a Funding Opportunity Announcement (FOA) to establish 5 new awards for the Research Evaluation and Commercialization Hubs (REACH) program to address the problems that hinder the critical, early steps necessary to translate novel scientific advances and discoveries into commercially viable diagnostics, devices, therapeutics, and tools that improve patient care and advance public health. The five awardees will participate in a technology development consortium that incorporates best practices from current pilot programs and fulfills the objectives of the Phase 0 Proof of Concept Partnership pilot program, in accordance with Section 5127 of the 2011 SBIR/STTR Reauthorization Act (P.L. 112-81) and reauthorized through FY 2022 within H.R. 5515 Sec 854. The REACH program advances FY2020 Administration Research and Development Budget Priorities, including educating and training a workforce for the 21st century economy, transferring technology from the laboratory to the marketplace, and partnering with industry and academia to advance the RandD enterprise.

High